Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREST phase 3 study of sasanlimab with or without BCG in high-risk non-muscle invasive bladder cancer
2023-509089-39-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of sasanlimab and bcg vaccine in non-muscle-invasive bladder cancer (NMIBC) (5 cohorts), sponsored by Pfizer. Primary endpoints: Event-free survival and Complete response. Planned start Jul 2020; status: authorised.
02
Drugs
sasanlimabbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2023-509089-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509089-39-00.